<DOC>
	<DOCNO>NCT00265200</DOCNO>
	<brief_summary>The purpose study evaluate new blood test way follow effect Zometa treat bone metastasis due lung cancer .</brief_summary>
	<brief_title>Using TRAP Evaluate Effect Zometa Bone Metastasis Due Lung Cancer</brief_title>
	<detailed_description>The purpose research study evaluate new blood test way follow effect Zometa treat bone metastasis . The blood test look protein , call TRAP , release blood stream breakdown bone . This study compare TRAP blood test blood test bone destruction .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>invasive lung cancer ( small cell nonsmall cell lung cancer ) osteolytic bone metastasis determine clinical exam , bone scan/XR age &gt; 18 year concurrent malignancy second primary renal failure ( serum creatinine &gt; 3mg/dl ) pregnancy active rheumatoid arthritis intolerance zoledronic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Zometa</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>lung cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>bone metabolic marker</keyword>
	<keyword>tartrate resistant acid phosphatase</keyword>
</DOC>